文献速递造血干细胞移植与细胞治疗

聚乙二醇化重组粒细胞集落刺激因子与重组人粒细胞集落刺激因子促进恶性血液病异基因造血干细胞移植后造血恢复的疗效与安全性比较研究

[Comparative study on the efficacy and safety between pegfilgrastim (PEG-rhG-CSF) and recombinant human granulocyte colony-stimulating factor in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation after hematological malignancy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2017-01-01

该研究纳入2015年6月至2016年11月接受异基因造血干细胞移植的恶性血液病患者157例,PEG-rhG-CSF组65例、rhG-CSF组92例。两组在中性粒细胞及血小板植入时间、GVHD发生率、复发率、无病生存率及总生存率方面均无显著差异,PEG-rhG-CSF可减少给药次数。

要点

  • PEG-rhG-CSF组中性粒细胞植入中位时间13.5(8~12)d,rhG-CSF组13(9~24)d,差异无统计学意义(P=0.393)。
  • 两组急性GVHD发生率23.1%(15/65)对34.8%(32/92),差异无统计学意义(P=0.115)。
  • 两组1年无病生存率62.5%对61.4%、总生存率67.4%对67.3%,差异均无统计学意义。

核心结论

  • 与rhG-CSF比较,PEG-rhG-CSF可减少给药次数,allo-HSCT后造血重建、GVHD发生率、复发率、无病生存率及总生存率无显著差异。

研究设计与样本

  • 以2015年6月至2016年11月住院治疗的157例接受allo-HSCT的恶性血液病患者为观察对象。
  • PEG-rhG-CSF组65例,在移植后第1天(+1 d)和+8 d各给予PEG-rhG-CSF 6 mg皮下注射。
  • rhG-CSF组92例,于+1 d开始给予rhG-CSF 5 μg·kg(-1)·d(-1)皮下注射,至中性粒细胞绝对计数>1.5×10(9)/L持续3 d停药。

主要发现

  • PEG-rhG-CSF组与rhG-CSF组中性粒细胞植入中位时间差异无统计学意义[13.5(8~12)d对13(9~24)d,P=0.393]。
  • PEG-rhG-CSF组与rhG-CSF组血小板植入中位时间差异无统计学意义[14(9~160)d对14(9~92)d,P=0.094]。
  • 两组粒细胞缺乏持续时间、粒细胞缺乏期发热例数及发热持续时间差异均无统计学意义(P=0.435,P=0.622,P=0.460)。
  • 两组移植后1个月内红细胞、单采血小板输注量差异无统计学意义(P=0.074,P=0.059)。
  • 两组急性GVHD、慢性GVHD、Ⅱ~Ⅳ度急性GVHD、慢性广泛型GVHD发生率差异均无统计学意义。

关键数值与推荐

  • 急性GVHD发生率:PEG-rhG-CSF组23.1%(15/65)对rhG-CSF组34.8%(32/92),P=0.115。
  • 慢性GVHD发生率:PEG-rhG-CSF组20.0%(13/65)对rhG-CSF组32.6%(30/92),P=0.081。
  • Ⅱ~Ⅳ度急性GVHD发生率:PEG-rhG-CSF组30.0%(13/65)对rhG-CSF组30.4%(28/93),P=0.287(原文摘要为28/93,正文为30/92,原文此处表述有矛盾)。
  • 慢性广泛型GVHD发生率:PEG-rhG-CSF组9.2%(6/65)对rhG-CSF组20.7%(19/92),P=0.135。
  • 1年无病生存率:PEG-rhG-CSF组62.5%对rhG-CSF组61.4%,P=0.478;1年总生存率:PEG-rhG-CSF组67.4%对rhG-CSF组67.3%,P=0.718。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To observe the efficacy and safety between Pegfilgrastim (PEG-rhG-CSF) and Recombinant human granulocyte colony stimulating factor (rhG-CSF) in hematological malignancy after allogeneic hematopoietic stem cell transplantation (allo-HSCT) . Methods: 157 patients after allo-HSCT were enrolled in this study from June 2015 to November 2016. Two agents of G-CSF were used to stimulate hematopoietic recovery after transplantation. There were 65 cases in PEG-rhG-CSF and 92 cases in rhG-CSF groups. Patients in PEG-rhG-CSF group were given a single subcutaneous dose of 6 mg on the first day and +8 d, while cases in rhG-CSF group were given in dose of 5 μg·kg(-1)·d(-1) by subcutaneous injection from +1 d continuing to neutrophils more than 1.5×10(9)/L, and then the indicators and survival rates in two groups after transplantation were compared. Results: ①There were no significant differences of the neutrophil implantation time[13.5 (8-12) d vs 13 (9-24) d, P=0.393] and platelet implantation time [14 (9-160) d vs 14 (9-92) d, P=0.094] between PEG-rhG-CSF and rhG-CSF groups respectively. There were no significant differences in terms of neutropenia period (P=0.435) , number of cases who got fever during neutropenia (P=0.622) , and the median time of fever in neutropenia period (P=0.460) , respectively between the two groups. There were no significant differences of erythrocyte and platelet transfusions (P=0.074, P=0.059) within 1 month after transplantation. ②There were no significant differences with regard to the incidences of acute GVHD[23.1% (15/65) vs 34.8% (32/92) , P=0.115], chronic GVHD[20.0% (13/65) vs 32.6% (32/92) , P=0.081], Ⅱ-Ⅳdegree of acute GVHD[30.0% (13/65) vs 30.4% (30/92) , P=0.287] and extensive chronic GVHD[9.2% (6/65) vs 20.7% (19/92) , P=0.135] between PEG-rhG-CSF and rhG-CSF groups. ③There were no significant differences in terms of disease free survival (DFS) (62.5% vs 61.4%, P=0.478) and overall survival (OS) (67.4% vs 67.3%, P=0.718) between PEG-rhG-CSF and rhG-CSF groups. ④There was no significant difference of the non-relapse mortality (NRM) between PEG-rhG-CSF and rhG-CSF groups[20.5% (95%CI 11.4%-37.0%) vs 32.6% (95%CI 22.2%-47.9%) , P=0.141]. The relapse rate was not statistically significant[14.9% (95%CI 7.4%-29.8%) vs 10.0% (95%CI 5.0%-20.0%) , P=0.299]. Conclusion: Compared with rhG-CSF, PEG-rhG-CSF could reduce the times of injection. There were no differences in terms of hematopoietic recovery, the incidence of GVHD, relapse rate, DFS and OS rates after allo-HSCT between two groups. 目的: 观察聚乙二醇化重组粒细胞集落刺激因子(PEG-rhG-CSF)与重组人粒细胞集落刺激因子(rhG-CSF)促进恶性血液病患者异基因造血干细胞移植(allo-HSCT)后造血恢复的效果及安全性。 方法: 以2015年6月至2016年11月住院治疗的157例接受allo-HSCT的恶性血液病患者为观察对象。PEG-rhG-CSF组(65例)在移植后第1天(+1 d)和+8 d各给予PEG-rhG-CSF 6 mg皮下注射;rhG-CSF组(92例)于+1 d开始给予rhG-CSF 5 μg·kg(-1)·d(-1)皮下注射,至中性粒细胞绝对计数>1.5×10(9)/L持续3 d停药。 结果: ①PEG-rhG-CSF组与rhG-CSF组比较,中性粒细胞植入、血小板植入中位时间差异均无统计学意义[(13.5(8~12)d对13(9~24)d,P=0.393;14(9~160)d对14(9~92)d,P=0.094],粒细胞缺乏持续时间、粒细胞缺乏期发热例数及粒细胞缺乏期发热持续时间差异均无统计学意义(P=0.435,P=0.622,P=0.460),移植后1个月内红细胞、单采血小板输注量差异无统计学意义(P=0.074,P=0.059)。②PEG-rhG-CSF组与rhG-CSF组比较,急性GVHD、慢性GVHD发生率差异均无统计学意义[23.1%(15/65)对34.8%(32/92),P=0.115;20.0%(13/65)对32.6%(30/92),P=0.081],Ⅱ~Ⅳ度急性GVHD、慢性广泛型GVHD的发生率差异均无统计学意义[30.0%(13/65)对30.4%(28/93),P=0.287;9.2%(6/65)对20.7%(19/92),P=0.135]。③PEG-rhG-CSF组与rhG-CSF组比较,1年无病生存和总生存率差异均无统计学意义[62.5%对61.4%,P=0.478;67.4%对67.3%,P=0.718]。④PEG-rhG-CSF组、rhG-CSF组比较,非复发死亡率差异无统计学意义[20.5%(95%CI 11.4%~37.0%)对32.6%(95%CI 22.2%~47.9%),P=0.141],复发率差异亦无统计学意义[14.9%(95%CI 7.4%~29.8%)对10.0%(95%CI 5.0%~20.0%),P=0.299]。 结论: 与rhG-CSF比较,PEG-rhG-CSF可减少给药次数,allo-HSCT后造血重建、GVHD发生率、复发率、无病生存率及总生存率无显著差异。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang F, Sun XD, Yuan L, et al. [Comparative study on the efficacy and safety between pegfilgrastim (PEG-rhG-CSF) and recombinant human granulocyte colony-stimulating factor in promoting hematopoietic recovery after allogeneic hematopoietic stem cell transplantation after hematological malignancy]. Zhonghua Xue Ye Xue Za Zhi. 2017. PMID: 29166733. doi:10.3760/cma.j.issn.0253-2727.2017.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。